Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 dose-ranging study in non-diabetic kidney disease
2020-002930-33Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avenciguat in chronic kidney disease (CKD) (4 arms), sponsored by Boehringer Ingelheim. Started Feb 2021; status: completed.
02
Drugs
avenciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-002930-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002930-33.